MonPsy&Moi: A Digital Platform for Collecting Patient-Reported Experience and Outcome Measures in Psychiatry
Launched by ASSISTANCE PUBLIQUE HOPITAUX DE MARSEILLE · Feb 4, 2025
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
The MonPsy&Moi trial is exploring a new digital platform designed to gather feedback from patients with mental health disorders like schizophrenia, bipolar disorders, and major depression. This platform, called MonPsy&Moi®, aims to improve mental health care in France by allowing patients to report their experiences and outcomes in real-time. The study will take place in two stages: the first will collect patient information without sharing it with doctors, while the second will provide doctors with this feedback to see if it helps improve patient care and reduce issues like relapses and healthcare costs.
To participate, individuals must be between 18 and 65 years old, live in France, and be receiving care at one of the 12 participating psychiatric facilities. They should have a confirmed diagnosis of a relevant mental health disorder and be able to understand French. Participants will complete adaptive questionnaires that cover their treatment experiences and overall quality of life. The trial aims to involve over 22,000 people in the first stage and about 1,100 in the second stage, ultimately hoping to enhance mental health services and guide future healthcare policies.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Residing in France. Age between 18 and 65 years at the time of inclusion.
- Receiving care in one of the 12 participating psychiatric facilities, with a confirmed diagnosis of:
- • Schizophrenia Spectrum Disorders (e.g., schizophrenia, schizoaffective disorder).
- • Bipolar Disorders. Major Depressive Disorders. A valid email address. Ability to read and understand French. Non-opposition to participating in the study (based on informed consent).
- Exclusion Criteria:
- * Primary diagnosis of an organic mental disorder, including:
- • Dementia. Stroke. Traumatic brain injury. Individuals deprived of liberty by judicial decision (e.g., incarcerated patients).
About Assistance Publique Hopitaux De Marseille
Assistance Publique - Hôpitaux de Marseille (AP-HM) is a leading public healthcare institution in France, dedicated to providing high-quality medical care and advancing research in various clinical fields. As a prominent sponsor of clinical trials, AP-HM is committed to fostering innovation and improving patient outcomes through rigorous scientific investigation. With a multidisciplinary approach, the institution collaborates with a network of healthcare professionals, researchers, and academic partners to facilitate cutting-edge studies that address critical health challenges. AP-HM's dedication to ethical standards and patient safety underscores its role as a trusted leader in clinical research and healthcare delivery.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Marseille, , France
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported